HLTH Nasdaq· Cue Health Inc
FundamentalsNews digest Peer analysis
HLTH Nasdaq· Cue Health Inc
Earnings report Q3 2023

HLTH Reports Decreased Revenue in Latest Quarter

Segments of revenue

In the latest quarter, HLTH reported total revenue of $17.5 million, compared to $69.6 million in the same quarter of the previous year. The decrease in revenue was primarily volume-related, as the company experienced a decline in COVID-19 testing demand. Revenue during the quarter was primarily driven by sales to private sector customers, amounting to $14.4 million.


Despite the decrease in revenue, HLTH demonstrated resilience by maintaining sales to private sector customers. The company's Cue Integrated Care Platform continues to be a key strength, enabling HLTH to empower people to live healthier lives. Management remains focused on their mission and is actively working to adapt to changing market conditions.


The decrease in revenue highlights the challenges faced by HLTH due to the tempering of COVID-19 testing demand. The company's reliance on testing revenue makes it vulnerable to fluctuations in testing volumes. Additionally, the decline in revenue may impact the company's profitability and ability to invest in research and development.


It is worth noting that HLTH's revenue decline is primarily attributed to the decrease in COVID-19 testing demand, which is a temporary and external factor. The company's long-term growth prospects may be influenced by the evolving landscape of healthcare technology and the demand for their Cue Integrated Care Platform.


HLTH reported a decrease in revenue in the latest quarter, primarily driven by lower COVID-19 testing demand. Despite this challenge, the company maintained sales to private sector customers and continues to focus on their mission of empowering people to live healthier lives. The decline in revenue highlights the vulnerability of HLTH's testing revenue, emphasizing the need for diversification and adaptation to changing market conditions. Overall, HLTH's performance in the latest quarter reflects the impact of external factors and the company's ongoing efforts to navigate the evolving healthcare technology landscape.

Source documents

Form 10-Q  filed on Nov 08, 2023
38 pages scanned

Reference data

Company financials Q3 revenue 17.5M
Analyst estimates Q3 EPS missed by -1.82%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.